// App-Quantinova.ai

330 : Development of a highly selective B/CRAF kinase inhibitor that exhibits antitumor activities in RAS and BRAF mutant tumors with minimal paradoxical activation

Researchers

Presenter

  • Wenlin Shao

Principal Investigators

  • Yun Feng

  • Giordano Caponigro

  • Savithri Ramurthy

  • Vesselina Cooke

  • Lesley Griner

  • Gisele Nishiguchi

  • Alice Rico

  • Ben Taft

  • Matthew Burger

  • Huw Tanner

  • Valery Polyakov

  • Brent Appleton

  • John Tellew

  • Richard Zang

  • Mohammad Hekmat-Nejad

  • Payman Amiri

  • Mallika Singh

  • Darrin Stuart

Medical Centers

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA

  • Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA

  • Genomics Institute of the Novartis Research Foundation, San Diego, CA.

  • Infectious Diseases, Novartis Institutes for BioMedical Research, Emeryville, CA

  • Oncology, Novartis Institutes for BioMedical Research, Emeryville, CA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • B-Raf proto-oncogene, serine/threonine kinase

  • Raf-1 proto-oncogene, serine/threonine kinase

  • GTPase Nras

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved